转氨酶明显升高的病因及诊治
Etiology and Diagnosis and Treatment of Markedly Elevated Transaminases
DOI: 10.12677/ACM.2023.13102352, PDF,   
作者: 谢晓月, 俞慧宏*:重庆医科大学附属第二医院消化内科,重庆
关键词: 氨基转移酶急性肝损伤病因诊断治疗Aminotransferase Acute Liver Injury Etiology Diagnosis Treatment
摘要: 肝功能检查已经是各个医院常规的血液生化检查,其中天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)水平异常通常提示有肝细胞的损伤,需要进一步检查明确病因,其病因对死亡率有显著影响,氨基转移酶水平明显升高是临床工作中常见的问题,明确氨基转移酶重度升高的病因是临床工作中的一大难题,我们主要概述了可能导致氨基转移酶重度升高的各种病因及诊治。
Abstract: Liver function tests have been routine blood biochemical tests in various hospitals, in which ab-normal levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are usually indicative of hepatocellular damage and require further investigation to clarify the etiology of the disease, which can have a significant impact on mortality, and a markedly elevated level of ami-notransferase is a common problem in the clinical workup. Defining the etiology of severely elevat-ed aminotransferases is a major challenge in the clinical workup, and we focus on outlining the var-ious etiological factors that may lead to severe elevation of aminotransferases and the diagnosis and management of the disease.
文章引用:谢晓月, 俞慧宏. 转氨酶明显升高的病因及诊治[J]. 临床医学进展, 2023, 13(10): 16797-16806. https://doi.org/10.12677/ACM.2023.13102352

参考文献

[1] Sookoian, S., Pirola, C.J., et al. (2015) Liver Enzymes, Metabolomics and Genome-Wide Association Studies: From Systems Biology to the Personalized Medicine. World Journal of Gastroenterology, 21, 711-725. [Google Scholar] [CrossRef] [PubMed]
[2] Kwo, P.Y., Cohen, S.M., Lim, J.K., et al. (2017) ACG Clinical Guide-line: Evaluation of Abnormal Liver Chemistries. The American Journal of Gastroenterology, 112, 18-35. [Google Scholar] [CrossRef] [PubMed]
[3] Giannini, E.G., Testa, R., Savarino, V., et al. (2005) Liver Enzyme Al-teration: A Guide for Clinicians. CMAJ, 172, 367- 379. [Google Scholar] [CrossRef] [PubMed]
[4] Horiuchi, S., Kamimoto, Y. and Morino, Y. (1985) Hepatic Clearance of Rate Liver Aspartate Aminotransferase Isoenzymes: Evidence for Endocytotic Uptake via Different Binding Sites on Sinusoidal Liver Cells. Hepatology, 5, 376- 382. [Google Scholar] [CrossRef] [PubMed]
[5] Smit, M.J., Wijnholds, J., Duursma, A.M., et al. (1986) Plasma Clearance of Mitochondrial Aspartate Aminotransferase in the Rate: Competition with Mitochondrial Malate Dehydro-genase. Biomedica Biochimica Acta, 45, 1557-1561.
[6] Wieme, R.J., Demeulenaere, L., et al. (1970) Enzyme Assays in Liver Disease. Journal of Clinical Pathology, 4, 51-59. [Google Scholar] [CrossRef] [PubMed]
[7] Reutemann, B., Gordon, F.D., et al. (2023) Evaluation of the Patient with Markedly Abnormal Liver Enzymes. Clinics in Liver Disease, 27, 1-16. [Google Scholar] [CrossRef] [PubMed]
[8] Kalas, M.A., Chavez, L., Leon, M., et al. (2021) Abnormal Liver Enzymes: A Review for Clinicians. World Journal of Hepatology, 13, 1688-1698. [Google Scholar] [CrossRef] [PubMed]
[9] Kwak, J.Y., Kim, H.G., Han, J.H., et al. (2023) Association of the Etiology and Peak Level of Markedly Elevated Aminotransferases with Mortality: A Multicenter Study. Hepatology Communications, 7, e0149. [Google Scholar] [CrossRef
[10] Dufour, D.R., Lott, J.A., Nolte, F.S., et al. (2000) Diagnosis and Monitoring of Hepatic Injury. II. Recommendations for Use of Laboratory Tests in Screening, Diagnosis, and Mon-itoring. Clinical Chemistry, 46, 2050-2068. [Google Scholar] [CrossRef] [PubMed]
[11] Ramachandran, A., Jaeschke, H., et al. (2019) Acetaminophen Hepatotoxicity. Seminars in Liver Disease, 39, 221-234. [Google Scholar] [CrossRef] [PubMed]
[12] Chalasani, N., Fontana, R.J., Bonkovsky, H.L., et al. (2008) Causes, Clinical Features, and Outcomes from a Prospective Study of Drug Induced Liver Injury in the United States. Gastroen-terology, 135, 1924-1934. [Google Scholar] [CrossRef] [PubMed]
[13] Navarro, V.J., Khan, I., Björnsson, E., et al. (2017) Liver Injury from Herbal and Dietary Supplements. Hepatology, 65, 363-373. [Google Scholar] [CrossRef] [PubMed]
[14] Teschke, R., Eickhoff, A., et al. (2015) Herbal Hepatotoxicity in Traditional and Modern Medicine: Actual Key Issues and New Encouraging Steps. Frontiers in Pharmacology, 6, Article No. 72. [Google Scholar] [CrossRef] [PubMed]
[15] (2019) EASL Clinical Practice Guidelines: Drug-Induced Liver In-jury. Journal of Hepatology, 70, 1222-1261. [Google Scholar] [CrossRef] [PubMed]
[16] Devarbhavi, H., Aitha, G.L., Treeprasertsuk, S., et al. (2021) Drug-Induced Liver Injury: Asia Pacific Association of Study of Liver Consensus Guidelines. Hepatology International, 15, 258-282. [Google Scholar] [CrossRef] [PubMed]
[17] Kleiner, D.E., et al. (2017) The Histopathological Evaluation of Drug-Induced Liver Injury. Histopathology, 70, 81-93. [Google Scholar] [CrossRef] [PubMed]
[18] Suzuki, A., Brunt, E.M., Kleiner, D.E., et al. (2011) The Use of Liver Bi-opsy Evaluation in Discrimination of Idiopathic Autoimmune Hepatitis versus Drug-Induced Liver Injury. Hepatology, 54, 931-939. [Google Scholar] [CrossRef] [PubMed]
[19] Kleiner, D.E., Chalasani, N.P., Lee, W.M., et al. (2014) Hepatic Histologi-cal Findings in Suspected Drug-Induced Liver Injury: Systematic Evaluation and Clinical Associations. Hepatology, 59, 661-670. [Google Scholar] [CrossRef] [PubMed]
[20] Björnsson, E., Kalaitzakis, E., Olsson, R., et al. (2007) The Impact of Eo-sinophilia and Hepatic Necrosis on Prognosis in Patients with Drug-Induced Liver Injury. Alimentary Pharmacology & Therapeutics, 25, 1411-1421. [Google Scholar] [CrossRef] [PubMed]
[21] Bonkovsky, H.L., Kleiner, D.E., Gu, J., et al. (2017) Clin-ical Presentations and Outcomes of Bile Duct Loss Caused by Drugs and Herbal and Dietary Supplements. Hepatology, 65, 1267-1277. [Google Scholar] [CrossRef] [PubMed]
[22] Aithal, G.P., Watkins, P.B. andrade, R.J., et al. (2011) Case Definition and Phenotype Standardization in Drug-Induced Liver Injury. Clinical Pharmacology & Therapeutics, 89, 806-815. [Google Scholar] [CrossRef] [PubMed]
[23] Fontana, R.J., Seeff, L.B., et al. (2010) Standardization of No-menclature and Causality Assessment in Drug-Induced Liver Injury: Summary of a Clinical Research Workshop. Hepa-tology, 52, 730-742. [Google Scholar] [CrossRef] [PubMed]
[24] Fontana, R.J. and Bari, K. (2017) Acute Liver Failure. In: Schiff, E.R., Maddrey, W.C. and Reddy, K.R., Eds., Schiff’s Diseases of the Liver, John Wiley & Sons, Hoboken, 411-431. [Google Scholar] [CrossRef
[25] Mallat, A., Zafrani, E.S., Metreau, J.M., et al. (1997) Terbinafine-Induced Prolonged Cholestasis with Reduction of Interlobular Bile Ducts. Digestive Diseases and Sciences, 42, 1486-1488. [Google Scholar] [CrossRef
[26] Lheureux, P.E.R., Penaloza, A., Zahir, S., et al. (2005) Science Review: Carnitine in the Treatment of Valproic Acid-Induced Toxicity—What Is the Evidence? Critical Care, 9, 431-440. [Google Scholar] [CrossRef] [PubMed]
[27] Lheureux, P.E.R., Hantson, P., et al. (2009) Carnitine in the Treatment of Valproic Acid-Induced Toxicity. Clinical Toxicology (Phila), 47, 101-111. [Google Scholar] [CrossRef] [PubMed]
[28] Ohtani, Y., Endo, F., Matsuda, I., et al. (1982) Carnitine Defi-ciency and Hyperammonemia Associated with Valproic Acid Therapy. The Journal of Pediatrics, 101, 782-785. [Google Scholar] [CrossRef
[29] Bohan, T.P., Helton, E., McDonald, I., et al. (2001) Effect of L-Carnitine Treatment for Valproate-Induced Hepatotoxicity. Neurology, 56, 1405-1409. [Google Scholar] [CrossRef
[30] Coulepis, A.G., Locarnini, S.A., Westaway, E.G., et al. (1982) Bi-ophysical and Biochemical Characterization of Hepatitis A Virus. Intervirology, 18, 107-127. [Google Scholar] [CrossRef] [PubMed]
[31] Coulepis, A.G. anderson, B., et al. (1987) Hepatitis A. Advances in Virus Research, 32, 129-169. [Google Scholar] [CrossRef
[32] Odenwald, M.A., Paul, S., et al. (2022) Viral Hepatitis: Past, Present, and Future. World Journal of Gastroenterology, 28, 1405-1429. [Google Scholar] [CrossRef] [PubMed]
[33] Cuthbert, J.A., et al. (2001) Hepatitis A: Old and New. Clinical Mi-crobiology Reviews, 14, 38-58. [Google Scholar] [CrossRef
[34] Ganem, D., Prince, A.M., et al. (2004) Hepatitis B Virus In-fection—Natural History and Clinical Consequences. The New England Journal of Medicine, 350, 1118-1129. [Google Scholar] [CrossRef
[35] Terrault, N.A., et al. (2018) Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology, 67, 1560-1599. [Google Scholar] [CrossRef] [PubMed]
[36] Zignego, A.L., et al. (1990) Amplification of Hepatitis Delta Virus RNA Sequences by Polymerase Chain Reaction: A Tool for Viral Detection and Cloning. Molecular and Cellular Probes, 4, 43-51. [Google Scholar] [CrossRef] [PubMed]
[37] Rosen, H.R., et al. (2011) Clinical Practice. Chronic Hepatitis C Infection. The New England Journal of Medicine, 364, 2429-2438. [Google Scholar] [CrossRef
[38] Armstrong, G.L., Wasley, A., et al. (2006) The Prevalence of Hepa-titis C Virus Infection in the United States, 1999 through 2002. Annals of Internal Medicine, 144, 705-714. [Google Scholar] [CrossRef] [PubMed]
[39] (2013) Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians. Morbidity and Mortality Weekly Report, 62, 362-365.
[40] Nimgaonkar, I., Ding, Q., et al. (2018) Hepatitis E Virus: Advances and Challenges. Nature Reviews Gastroenterology & Hepatology, 15, 96-110. [Google Scholar] [CrossRef] [PubMed]
[41] Zhang, J., Zhang, X.F., Huang, S.J., et al. (2015) Long-Term Efficacy of a Hepatitis E Vaccine. The New England Journal of Medicine, 372, 914-922. [Google Scholar] [CrossRef
[42] Hewlett, G., Hallenberger, S., Rübsamen-Waigmann, H., et al. (2004) Antivirals against DNA Viruses (Hepatitis B and the Herpes Viruses). Current Opinion in Pharmacology, 4, 453-464. [Google Scholar] [CrossRef] [PubMed]
[43] Kwak, J.Y., et al. (2023) Association of the Etiology and Peak Level of Markedly Elevated Aminotransferases with Mortality: A Multicenter Study. Hepatology Communications, 7, e0149. [Google Scholar] [CrossRef
[44] Breu, A.C., Patwardhan, V.R., Nayor, J., et al. (2019) A Multicenter Study into Causes of Severe Acute Liver Injury. Clinical Gastroenterology and Hepatology, 17, 1201-1203. [Google Scholar] [CrossRef] [PubMed]
[45] Gibson, P.R. and Dudley, F.J. (1984) Ischemic Hepatitis: Clinical Features, Diagnosis and Prognosis. Australian and New Zealand Journal of Medicine, 14, 822-825. [Google Scholar] [CrossRef] [PubMed]
[46] Gitlin, N. and Serio, K.M. (1992) Ischemic Hepatitis: Widening Horizons. The American Journal of Gastroenterology, 87, 831-836.
[47] Shribman, S., Poujois, A., Band-mann, O., et al. (2021) Wilson’s Disease: Update on Pathogenesis, Biomarkers and Treatments. Journal of Neurology, Neurosurgery and Psychiatry, 92, 1053-1061. [Google Scholar] [CrossRef] [PubMed]
[48] Gu, M., Cooper, J.M., Butler, P., et al. (2000) Oxida-tive-Phosphorylation Defects in Liver of Patients with Wilson’s Disease. The Lancet, 356, 469-474. [Google Scholar] [CrossRef
[49] Bandmann, O., Weiss, K.H., Kaler, S.G., et al. (2015) Wil-son’s Disease and Other Neurological Copper Disorders. The Lancet Neurology, 14, 103-113. [Google Scholar] [CrossRef
[50] Yuan, X.Z., Yang, R.M., Wang, X.P., et al. (2021) Man-agement Perspective of Wilson’s Disease: Early Diagnosis and Individualized Therapy. Current Neuropharmacology, 19, 465-485. [Google Scholar] [CrossRef
[51] Członkowska, A., Litwin, T., Dusek, P., et al. (2018) Wilson Disease. Nature Reviews Disease Primers, 4, Article No. 21. [Google Scholar] [CrossRef] [PubMed]
[52] Eisenbach, C., Sieg, O., Stremmel, W., et al. (2007) Diagnostic Criteria for Acute Liver Failure Due to Wilson Disease. World Journal of Gastroenterology, 13, 1711-1714. [Google Scholar] [CrossRef] [PubMed]
[53] Ostapowicz, G., Fontana, R.J., et al. (2002) Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States. Annals of Internal Medicine, 137, 947-954. [Google Scholar] [CrossRef] [PubMed]
[54] (2012) EASL Clinical Practice Guidelines: Wilson’s Disease. Journal of Hepatology, 56, 671-685. [Google Scholar] [CrossRef] [PubMed]
[55] Ferenci, P., Caca, K., Loudianos, G., et al. (2003) Diagnosis and Phenotypic Classification of Wilson Disease. Liver International, 23, 139-142. [Google Scholar] [CrossRef] [PubMed]
[56] Ferenci, P., Steindl-Munda, P., Vogel, W., et al. (2005) Diagnostic Value of Quantitative Hepatic Copper Determination in Patients with Wilson’s Disease. Clinical Gastroenter-ology and Hepatology, 3, 811-818. [Google Scholar] [CrossRef
[57] Roberts, E.A., Schilsky, M.L., et al. (2008) Diagnosis and Treatment of Wilson Disease: An Update. Hepatology, 47, 2089-2111. [Google Scholar] [CrossRef] [PubMed]
[58] Dzieżyc, K., Litwin, T., Chabik, G., et al. (2014) Families with Wilson’s Disease in Subsequent Generations: Clinical and Genetic Analysis. Movement Disorders, 29, 1828-1832. [Google Scholar] [CrossRef] [PubMed]
[59] Schilsky, M.L., et al. (1994) Liver Transplantation for Wilson’s Disease: Indications and Outcome. Hepatology, 19, 583-587. [Google Scholar] [CrossRef] [PubMed]
[60] Bellary, S., Hassanein, T., et al. (1995) Liver Transplantation for Wilson’s Disease. Journal of Hepatology, 23, 373- 381. [Google Scholar] [CrossRef] [PubMed]
[61] Ahmad, A., Torrazza-Perez, E., Schilsky, M.L., et al. (2017) Liver Transplantation for Wilson Disease. In: Handbook of Clinical Neurology, Vol. 142, Elsevier, Amsterdam, 193-204. [Google Scholar] [CrossRef
[62] Aydinli, M., Bayraktar, Y., et al. (2007) Budd-Chiari Syndrome: Etiology, Pathogenesis and Diagnosis. World Journal of Gastroenterology, 13, 2693-2696. [Google Scholar] [CrossRef] [PubMed]
[63] (2016) EASL Clinical Practice Guidelines: Vascular Diseases of the Liver. Journal of Hepatology, 64, 179-202. [Google Scholar] [CrossRef] [PubMed]
[64] Janssen, H.L.A., Garcia-Pagan, J.C., Elias, E., et al. (2003) Budd-Chiari Syndrome: A Review by an Expert Panel. Journal of Hepatology, 38, 364-371. [Google Scholar] [CrossRef
[65] Hernández-Guerra, M., Turnes, J., Rubinstein, P., et al. (2004) PTFE-Covered Stents Improve TIPS Patency in Budd- Chiari Syndrome. Hepatology, 40, 1197-1202. [Google Scholar] [CrossRef] [PubMed]
[66] Grus, T., Lambert, L., Grusová, G., et al. (2017) Budd-Chiari Syndrome. Prague Medical Report, 118, 69-80. [Google Scholar] [CrossRef] [PubMed]
[67] Murad, S.D., Plessier, A., Hernandez-Guerra, M., et al. (2009) Etiology, Management, and Outcome of the Budd- Chiari Syndrome. Annals of Internal Medicine, 151, 167-175. [Google Scholar] [CrossRef] [PubMed]
[68] DeLeve, L.D., Valla, D.C., et al. (2009) Vascular Disorders of the Liver. Hepatology, 49, 1729-1764. [Google Scholar] [CrossRef] [PubMed]
[69] Northup, P.G., Garcia-Pagan, J.C., Garcia-Tsao, G., et al. (2021) Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients with Liver Disease: 2020 Practice Guid-ance by the American Association for the Study of Liver Diseases. Hepatology, 73, 366-413. [Google Scholar] [CrossRef] [PubMed]
[70] Jones, R.J., Lee, K.S., Beschorner, W.E., et al. (1987) Venoocclusive Dis-ease of the Liver Following Bone Marrow Transplantation. Transplantation, 44, 778-783. [Google Scholar] [CrossRef] [PubMed]
[71] Mack, C.L., Adams, D., Assis, D.N., et al. (2020) Di-agnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines from the American Association for the Study of Liver Diseases. Hepatology, 72, 671-722. [Google Scholar] [CrossRef] [PubMed]
[72] Kim, B.H., Choi, H.Y., Ki, M., et al. (2017) Population-Based Prevalence, Incidence, and Disease Burden of Autoimmune Hepatitis in South Korea. PLOS ONE, 12, e0182391. [Google Scholar] [CrossRef] [PubMed]
[73] Takahashi, A., Arinaga-Hino, T., Ohira, T., et al. (2017) Auto-immune Hepatitis in Japan: Trends in a Nationwide Survey. Journal of Gastroenterology, 52, 631-640. [Google Scholar] [CrossRef] [PubMed]
[74] Kim, B.H., Kim, Y.J., et al. (2013) Clinical Features of Autoim-mune Hepatitis and Comparison of Two Diagnostic Criteria in Korea: A Nationwide, Multicenter Study. Journal of Gas-troenterology and Hepatology, 28, 128-134. [Google Scholar] [CrossRef] [PubMed]
[75] Muratori, P., Carbone, M., Stangos, G., et al. (2018) Clin-ical and Prognostic Implications of Acute Onset of Autoimmune Hepatitis: An Italian Multicentre Study. Digestive and Liver Disease, 50, 698-702. [Google Scholar] [CrossRef] [PubMed]
[76] (2022) Guidelines on the Diagnosis and Management of Autoim-mune Hepatitis (2021). Chinese Journal of Hepatology, 30, 482-492.
[77] Lemos-Bonotto, M.D., Valle-Tovo, C., et al. (2018) A Systematic Review and Meta-Analysis of Second-Line Immunosuppressants for Autoimmune Hepatitis Treat-ment. European Journal of Gastroenterology & Hepatology, 30, 212- 216. [Google Scholar] [CrossRef
[78] Nicoll, A.J., Roberts, S.K., Lim, R., et al. (2019) Beneficial Response to Mycophenolate Mofetil by Patients with Autoimmune Hepatitis Who Have Failed Standard Therapy, Is Pre-dicted by Older Age and Lower Immunoglobulin G and INR Levels. Alimentary Pharmacology & Therapeutics, 49, 1314-1322. [Google Scholar] [CrossRef] [PubMed]
[79] Bangaru, S., Thiele, D., Sreenarasimhaiah, J., et al. (2017) Se-vere Elevation of Liver Tests in Choledocholithiasis: An Uncommon Occurrence with Important Clinical Implications. Journal of Clinical Gastroenterology, 51, 728-733. [Google Scholar] [CrossRef
[80] Björnsson, H.K., Olafsson, S., Bergmann, O.M., et al. (2016) A Prospective Study on the Causes of Notably Raised Alanine Aminotransferase (ALT). Scandinavian Journal of Gastroenterology, 51, 594-600. [Google Scholar] [CrossRef] [PubMed]
[81] Björnsson, H.K., Björnsson, E.S., et al. (2019) A Significant Proportion of Patients with Choledocholithiasis Have Markedly Elevated Alanine Aminotransferase. Scandinavian Jour-nal of Gastroenterology, 54, 1155-1159. [Google Scholar] [CrossRef] [PubMed]
[82] Huh, C.W., Jang, S.I., Lim, B.J., et al. (2016) Clinicopatho-logical Features of Choledocholithiasis Patients with High Aminotransferase Levels without Cholangitis: Prospective Comparative Study. Medicine (Baltimore), 95, e5176. [Google Scholar] [CrossRef
[83] Souza, M.E., et al. (1990) Serum Transaminase Levels in the Acute Phase of Chronic Extrahepatic Cholestasis. Brazilian Journal of Medical and Biological Research, 23, 995-997.
[84] Aronsen, K.F., et al. (1961) Liver Function Studies during and after Complete Extra-Hepatic Biliary Ob-struction in the Dog. Acta chirurgica Scandinavica Supplementum, 275, 1-114.